Related Experiment Video
Updated: Jul 16, 2026
04:40
Venous Thrombosis Assay in a Mouse Model of Cancer
Published on: January 5, 2024
Cancer and venous thromboembolism
1Department of Hematology, University Hospital - Plovdid, Bulgaria.
Summary
Cancer patients frequently experience blood clots due to complex interactions affecting the hemostatic system. New anticoagulant therapies targeting specific coagulation factors offer improved management for thrombosis in cancer.
Area of Science:
- Hematology
- Oncology
- Thrombosis Research
Background:
- Coagulation abnormalities, both inherited and acquired, can lead to clinical issues.
- Cancer is a significant risk factor for venous thrombosis, with prevalence estimates ranging from 3-18% among patients.
- Pathogenic mechanisms involve complex interactions between tumor cells, the patient, and the hemostatic system.
Purpose of the Study:
- To review the mechanisms of thrombosis in cancer patients.
- To discuss current and emerging therapeutic strategies for managing thrombosis in this population.
Main Methods:
- Literature review of pathogenic mechanisms of thrombosis in cancer.
- Analysis of current treatment protocols, including low-molecular-weight heparin (LMWH).
- Exploration of novel anticoagulant targets within the coagulation cascade.
Main Results:
- Thrombosis in cancer involves tumor cell interactions, hemostatic system activation, and external factors like venous access devices and chemotherapy.
- Subcutaneous low-molecular-weight heparin (LMWH) is now the standard initial treatment over unfractionated heparin (UFH).
- New anticoagulant agents targeting specific factors (e.g., Factor Xa, thrombin) are under development.
Conclusions:
- Understanding the intricate mechanisms of thrombosis in cancer is crucial for effective management.
- Optimizing anticoagulant therapy, including exploring novel agents, holds promise for improving outcomes in cancer patients with thrombosis.
- Targeting specific steps in the coagulation cascade may lead to safer and more effective anticoagulation.
Related Concept Videos
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
01:19Pulmonary Embolism I: Introduction
A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...
01:29Pulmonary Embolism I: Introduction
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...